

# UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

1cc69 U.S. PTO  
09/620561  
07/20/00

Page 1

Atty. Docket No. 22441.00001

Assistant Commissioner of Patents  
Box Patent Applications  
Washington, D.C. 20231

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): Michael C. Kiefer

Title of Invention: EXPRESSION AND USE OF HUMAN FIBROBLAST RECEPTOR

☐ Continuation

☒ Divisional

☐ Continuation-in-Part

of prior application No. 08/439,992, filed May 12, 1995

1. ☒ Specification 29 pages (including specification, claims, abstract) / 21 claims (5 independent)

2. ☒ Declaration/Power of Attorney:

☒ Copy from Prior Application (for continuation or divisional application)

☐ Newly Executed Declaration (for CIP application)

☐ Deferred under 37 C.F.R. § 1.53(f)

☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)

☒ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein

3. ☒ 2 Distinct sheets of ☒ Formal ☐ Informal Drawings

4. ☒ Preliminary Amendment

5. ☒ Information Disclosure Statement

☒ Form 1449

☐ A copy of each cited prior art reference

6. ☒ Assignment

☐ Assignment with Cover Sheet attached

☒ Assignment filed in prior application. Application assigned to: **Chiron Corporation**

7. ☐ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

1cc803 U.S. PTO  
07/20/00

09/620561  
07/20/00

# UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 22441.00001

Country	Application Number	Date of Filing (day, month, year)
U.S.	08/315,686	30 September 1994
U.S.	08/046,020	12 April 1993
U.S.	07/640,029	11 January 1991

8. ☐ Priority document(s)
9. ☐ Small Entity Statement
- ☐ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
- ☐ is attached
- ☐ is no longer claimed
10. ☐ Microfiche Computer Program (Appendix)
11. ☒ Nucleotide and/or Amino Acid Sequence Submission
- ☐ Computer Readable Copy
- ☒ Paper Copy (identical to computer copy)
- ☒ Statement verifying identity of above copies

## 12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$690.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	6	18.00	\$108.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	7	78.00	\$546.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	260.00	\$0.00
Subtotal - Filing Fee Due			\$1,344.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$0.00
<b>TOTAL FILING FEE DUE</b>			<b>\$1,344.00</b>
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
<b>GRAND TOTAL DUE</b>			<b>\$1,344.00</b>

**under 37 C.F.R. § 1.53(b)**

**Atty. Docket No. 22441.00001**

- Joseph H. Guth  
Chiron Corporation  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-3888  
Facsimile: (510) 655-3542

By: Lisa M. Hemmendinger  
Lisa M. Hemmendinger  
Reg. No. 42,653

LMH/ama

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
KIEFER *et al.* ) Group Art Unit: TBA  
Serial No. TBA ) Examiner: TBA  
Filed: July 20, 2000 ) Atty. Docket No. 22441.00001  
For: **EXPRESSION AND USE OF HUMAN FIBROBLAST  
GROWTH FACTOR RECEPTOR**

**PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Please enter the following amendments before examining the application referenced above.

**IN THE CLAIMS**

Please cancel claims 1-21 and add the following new claims:

~~--22.~~ A composition consisting essentially of a polynucleotide having a sequence encoding a human fibroblast growth factor receptor (hFGFr) comprising three immunoglobulinlike domains, wherein the sequence is selected from the group consisting of:

(a) the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTG TAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,  
contacting the cDNA library with the probes under conditions that permit hybridization, and  
identifying and isolating the candidate that hybridizes to both oligonucleotides probes;  
(b) the sequence encoding SEQ ID NO: 1;  
(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence  
of (a), wherein the differences between the sequences of (c) and (a) are confined to changes in  
nucleotide sequence which do not result in a change in the corresponding encoded amino acid of  
hFGFr.--

--23. The composition of claim 22, wherein the polynucleotide has a sequence of a cDNA  
molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTG TAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG;

providing a cDNA library of candidates;

contacting the cDNA library with the probes under conditions that permit  
hybridization; and

identifying and isolating the candidate that hybridizes to both oligonucleotide  
probes.--

--24. The composition of claim 22, wherein the polynucleotide has a sequence that encodes  
the amino acid sequence of SEQ ID NO: 1.--

--25. The composition of claim 22, wherein the polynucleotide has a sequence encoding  
hFGFr substantially the same as the sequence of (a), wherein the differences between said sequence  
and the sequence of (a) are confined to changes in nucleotide sequence which do not result in a

change in the corresponding encoded amino acid of hFGFr.--

--26. A composition consisting essentially of a polynucleotide comprising a sequence encoding an extracellular region of a human fibroblast growth factor receptor (hFGFr) comprising three immunoglobulinlike domains, wherein the sequence is selected from the group consisting of:

(a) the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

CCACCTCTAGAGGATCCACTGGGATGTGGAGCTGGAAGTGC and  
GTAAGCGGCCGCGGATCCTTACTACTCCAGGTACAGGGGCGA;

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that permit  
hybridization, and

isolating the candidate that hybridizes to both oligonucleotide probes;

(b) the sequence encoding amino acids 1 to 374 of SEQ ID NO: 1;

(c) a sequence encoding the extracellular region of hFGFr having a sequence substantially the same as the sequence of (a), the differences between the sequences (c) and (a) being confined to changes in nucleotide sequence which do not result in a change in the encoded amino acid of hFGFr.--

--27. The composition of claim 26, wherein the polynucleotide has a sequence that is the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

CCACCTCTAGAGGATCCACTGGGATGTGGAGCTGGAAGTGC and  
GTAAGCGGCCGCGGATCCTTACTACTCCAGGTACAGGGGCGA,

providing a cDNA library of candidates;

contacting the cDNA library with the probes under conditions that permit hybridization; and

identifying and isolating the candidate that hybridizes to both oligonucleotide probes.--

--28. The composition of claim 27, wherein the cDNA molecule is isolated and identified by polymerase chain reaction.--

--29. The composition of claim 26, wherein the polynucleotide has a sequence that encodes amino acids 1 to 374 or SEQ ID NO: 1.--

--30. The composition of claim 26, wherein the polynucleotide has a sequence that encodes the extracellular region of hFGFr having a sequence substantially the same as the sequence of (a), wherein the differences between the sequences (c) and (a) are confined to changes in nucleotide sequence which do not result in a change in the encoded amino acid of hFGFr.--

--31. A composition consisting essentially of a recombinant human fibroblast growth factor receptor (hFGFr) vector comprising:

- (a) an origin of replication; and
- (b) a nucleic acid encoding means for hFGFr comprising three immunoglobulinlike domains,

wherein the origin of replication is operably linked to the nucleic acid encoding means.--

--32. The composition of claim 31, wherein the nucleic acid encoding means is a polynucleotide having a sequence selected from the group consisting of:

- (a) a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTG TAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that permit

hybridization, and

identifying and isolating the candidate that hybridizes to both

oligonucleotide probes;

(b) a sequence that encodes SEQ ID NO: 1.

(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence of (a), wherein the differences between said sequence and the sequence of (a) are confined to changes in nucleotide sequence which do not result in a change in the corresponding encoded amino acid of hFGFr.--

--33. The composition of claim 31, wherein the recombinant vector is an expression vector capable of producing a human fibroblast growth factor receptor comprising three immunoglobulinlike domains in a host cell, wherein the vector further comprises a promoter operable in the host cell and operably linked to the nucleic acid encoding means.--

--34. The composition of claim 31, wherein the recombinant vector is a nonlytic viral vector capable of infecting a host cell, wherein the vector comprises a viral origin of replication.--

--35. A composition consisting essentially of a recombinant human fibroblast growth factor receptor (hFGFr) vector comprising

(a) an origin of replication; and

(b) a nucleic acid encoding means for hFGFr comprising an extracellular region

wherein the origin of replication is operably linked to the nucleic acid encoding means.--

--36. The composition of claim 35, wherein the nucleic acid encoding means is a



polynucleotide having a sequence selected from the group consisting of:

- (a) the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

CCACCTCTAGAGGATCCACTGGGATGTGGAGCTGGAAGTGC and

GTAAGCGGCCGCGGATCCTTACTACTCCAGGTACAGGGGCGA;

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that permit

hybridization, and

isolating the candidate that hybridizes to both oligonucleotide probes;

- (b) the sequence encoding amino acids 1 to 374 of SEQ ID NO: 1;

(c) a sequence encoding the extracellular region of hFGFr having a sequence substantially the same as the sequence of (a), the differences between the sequences (c) and (a) being confined to changes in nucleotide sequence which do not result in a change in the encoded amino acid of hFGFr.--

--37. A method of isolating a polynucleotide having a sequence encoding a human fibroblast growth factor receptor (hFGFr) comprising three immunoglobulinlike domains, wherein the method comprises:

providing oligonucleotide probes

ATAACGGACCTTGTAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that permit

hybridization, and

identifying and isolating the candidate that hybridizes to both oligonucleotide probes.--

--38. A method for isolating a polynucleotide having a sequence encoding an extracellular region of a human fibroblast growth factor receptor (hFGFr) comprising three immunoglobulinlike domains, wherein the method comprises:

providing oligonucleotide probes

CCACCTCTAGAGGATCCACTGGGATGTGGAGCTGGAAGTGC and  
GTAAGCGGCCGCGGATCCTTACTACTCCAGGTACAGGGGCGA;

providing a cDNA library of candidates;

contacting the cDNA library with the probes under conditions that permit hybridization; and

isolating the candidate that hybridizes to both oligonucleotide probes.--

--39. The method of claim 38, wherein the method further comprises contacting the cDNA library and the probes under conditions that permit polymerase chain reaction.--

--40. A host cell comprising a recombinant human fibroblast growth factor receptor (hFGFr) vector comprising:

- (a) an origin of replication operable in the host cell; and
- (b) a nucleic acid encoding means for hFGFr comprising three immunoglobulinlike domains,

wherein the origin of replication is operably linked to the nucleic acid encoding means.--

--41. The host cell of claim 40, wherein the nucleic acid encoding means is a polynucleotide having a sequence selected from the group consisting of:

- (a) the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTGTAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that permit

hybridization, and

identifying and isolating the candidate that hybridizes to both

oligonucleotide probes;

(b) the sequence encoding SEQ ID NO: 1; and

(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence of (a), wherein the differences between the sequences of (c) and (a) are confined to changes in nucleotide sequence which do not result in a change in the corresponding encoded amino acid of hFGFr.--

--42. A host cell comprising a recombinant human fibroblast growth factor receptor (hFGFr) vector that comprises:

(a) an origin of replication; and

(b) a nucleic acid encoding means for hFGFr comprising three immunoglobulinlike domains,

wherein the origin of replication is operably linked to the nucleic acid encoding means.--

--43. The host cell of claim 42, wherein the nucleic acid encoding means is a polynucleotide having the sequence selected from the group consisting of

(a) a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTGTAGCCTCCAATTCTGTG and  
GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,  
contacting the cDNA library with the probes under conditions that permit  
hybridization, and  
identifying and isolating the candidate that hybridizes to both  
oligonucleotide probes;

(b) a sequence that encodes SEQ ID NO: 1; and

(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence  
of (a), wherein the differences between said sequence and the sequence of (a) are confined to  
changes in nucleotide sequence which do not result in a change in the corresponding encoded amino  
acid of hFGFr.--

~~44~~. A method of producing a human fibroblast growth factor receptor (hFGFr)  
comprising three immunoglobulinlike domains, comprising:

- (a) providing a host cell that comprises  
an origin of replication operable in the host cell, and  
a nucleic acid encoding means for hFGFr comprising three  
immunoglobulinlike domains,

wherein the origin of replication is operably linked to the nucleic acid encoding means;

(b) culturing the host cell in a suitable culture medium and under suitable  
conditions permitting the expression of the nucleic acid encoding means; and

(c) recovering the polypeptide from the medium and cells.--

--45. The method of claim 44, wherein the nucleic acid encoding means is a polynucleotide

having a sequence selected from the group consisting of:

- (a) the sequence of a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTGTAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that

permit hybridization, and

identifying and isolating the candidate that hybridizes to both

oligonucleotide probes;

- (b) the sequence encoding SEQ ID NO: 1; and

(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence of (a), wherein the differences between the sequences of (c) and (a) are confined to changes in nucleotide sequence which do not result in a change in the corresponding encoded amino acid of hFGFr.--

--46. A method of producing an extracellular human fibroblast growth factor receptor (hFGFr) comprising three immunoglobulinlike domains, comprising

(a) providing a recombinant human fibroblast growth factor receptor (hFGFr) vector that comprises

an origin of replication, and

a nucleic acid encoding means for an extracellular hFGFr comprising three immunoglobulinlike domains,

wherein the origin of replication is operably linked to the nucleic acid encoding means;

(b) culturing the host cell in a suitable culture medium and under suitable conditions permitting the expression of the nucleic acid encoding means; and

(c) recovering the polypeptide from the medium and cells.--

--47. The method of claim 46, wherein the nucleic acid encoding means is a polynucleotide having a sequence selected from the group consisting of:

(a) a cDNA molecule or complement obtainable as follows:

providing oligonucleotide probes

ATAACGGACCTTGTAGCCTCCAATTCTGTG and

GCGGCGTTTGAGTCCGCCATTGGCAAGCTG,

providing a cDNA library of candidates,

contacting the cDNA library with the probes under conditions that

permit hybridization, and

identifying and isolating the candidate that hybridizes to both oligonucleotide probes;

(b) a sequence that encodes SEQ ID NO: 1; and

(c) a sequence encoding hFGFr having a sequence substantially the same as the sequence of (a), wherein the differences between said sequence and the sequence of (a) are confined to change in nucleotide sequence which do not result in a change in the corresponding encoded amino acid of hFGFr.--

#### **IN THE SPECIFICATION**

Please insert the following sentence after the title:

--This application is a division of Serial No. 08/479,992 filed May 12, 1995, which is a continuation of U.S. Serial no. 08/315,686, filed September 30, 1994, which is a continuation of

U.S. Serial No. 08/046,020, filed April 12, 1993, which is a continuation of U.S. Serial No. 07/640, 029, filed January 11, 1991, now U.S. Patent No. 5,229,501.


### Remarks

Support for the claims can be found, for example, at page 8, lines 14-27, and at page 13, line 1 to page 19, line 15.

Please address all correspondence in this application to Joseph H. Guth, Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097, telephone (510) 923-3888, facsimile (510) 655-3542.

Respectfully submitted,

Date: July 20, 2000

By:   
Lisa M. Hemmendinger  
Reg. No. 42,653

Banner & Witcoff, Ltd.  
1001 G Street, N.W.  
Eleventh Floor  
Washington, D.C. 20001-4597  
telephone (202) 508-9100  
facsimile (202) 508-9299

I hereby certify that this New Application and the documents referred to as enclosures are being deposited with the United States Postal Service on this date January 11, 1991 in an envelope bearing "Express Mail Post Office To Addressee" Mailing Label Number RB561501413 addressed to: Patent Application, Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Barbara G. McClung

Date

Atty Dkt CH-165  
PATENT

5

EXPRESSION AND USE OF HUMAN  
FIBROBLAST GROWTH FACTOR RECEPTOR

10

Description

Technical Field

This invention relates to the fields of molecular biology and pharmaceutical research. More specifically, this invention relates to the recombinant expression of a human high-affinity fibroblast growth factor (FGF) receptor, and its use in combination with glycosaminoglycans to model compounds capable of mimicking FGF binding.

20

Background of the Invention

The fibroblast growth factors (FGFs) are a family of structurally related polypeptides that regulate the growth and differentiation of a diverse number of cell types. Acidic and basic FGFs are mitogenic for cell types of mesenchymal, epithelial and neural origin (K. Thomas, FASEB J (1987) 1:434-440; D. Gospodarowicz, Meth Enzymol (1987) 147:106-119). The more recently discovered members of the FGF family have been implicated in early developmental processes and in epithelial cell growth and maintenance (R. Moore et al, EMBO J (1986) 5:919-924; A. Jakobovits et al, Proc Natl Acad Sci USA (1986) 83:7806-7810; P.W. Finch et al, Science (1989) 245:752-755). Currently, the FGF family consists of seven distinct gene



products including acidic and basic FGFs (M. Jaye et al, Science (1986) 233:541-545; J.A. Abraham et al, Science (1986) 233:545-548; J.A. Abraham et al, EMBO J (1986) 5:2523-2528), the product of the int-2 oncogene (R. Moore et al, *supra*; A. Jakobovits et al, *supra*), a growth factor identified from Kaposi's sarcoma DNA (hst-1 or KS-FGF) (P.D. Bovi et al, Cell (1987) 50:729-737; M. Taira et al, Proc Natl Acad Sci USA (1987) 84:2980-2984), FGF-5 (X. Zhan et al, Mol Cell Biol (1988) 8:3487-3495), FGF-6 (I. Marics et al, Oncogene (1989) 4:335-340) and keratinocyte growth factor, KGF or FGF-7 (P.W. Finch et al, *supra*).

The large number of FGFs and their diverse spectrum of activities suggests that several receptors may mediate their effects on cells. Indeed, for the acidic and basic FGFs themselves, two classes of receptors have been well documented which are distinguished by their affinities for FGF. For example, the binding of bFGF to a high affinity site on baby hamster kidney (BHK) cells occurs with a dissociation constant in the 20 pM range, whereas bFGF binding to the low affinity site occurs with a dissociation constant in the 2 nM range, and is released with 2M NaCl. The FGF receptor has been implicated as the entry portal for Herpes simplex virus (HSV). Several high affinity FGF receptor cDNAs have been cloned (P.L. Lee et al, Science (1989) 245:57-60; E. Pasquale & S.J. Singer, Proc Natl Acad Sci USA (1989) 86:5449-5453; M. Ruta et al, Oncogene (1988) 3:9-15; H.H. Reid et al, Proc Natl Acad Sci USA (1990) 87:1596-1600; A. Isacchi et al, Nuc Acids Res (1990) 18:1906; D.E. Johnson et al, Mol Cell Biol (1990) 10:4728-4736) and shown by structural homology to be members of the cell surface protein-tyrosine kinase family of proteins. This group of membrane-bound proteins are thought to play an important role in the regulation of cell growth. They include the receptors for

epidermal growth factor, platelet-derived growth factor, colony stimulating factor-1, insulin, and insulin-like growth factor-1 (for recent review see A. Ullrich & J. Schlessinger, *Cell* (1990) 61:203-212).

5           Structural analyses of the extracellular regions of  
the chicken FGF receptor cDNA suggests that the FGF receptors  
also belong to the immunoglobulin supergene family (P.L. Lee et  
*al, supra*). Accordingly, Reid et al, (*supra*) have found sev-  
10       eral forms of the bFGF receptor mRNA in developing mouse brain  
that contain either two or three immunoglobulin-like domains.  
Moreover, they detected a region of sequence variability  
between the first and second immunoglobulin-like domains. In  
this case, amino acids 148 and 149 are sometimes deleted in the  
predicted sequences for proteins that contain 2 immunoglobulin-  
15       like domains. Recently, four forms of the cDNA encoding the  
human two immunoglobulin-like domain FGF receptor have been  
identified (D.E. Johnson et al, *supra*). Two of these forms are  
homologous to the mouse two immunoglobulin-like domain FGF  
receptor in that they vary at amino acids 148 and 149 (H.H.  
20       Reid et al, *supra*). While the other two forms of the human FGF  
receptor also vary at these amino acids, they are unique in  
that they lack a transmembrane domain and the cytoplasmic  
tyrosine kinase domain. More recently, a fifth form of the  
human FGF receptor cDNA has also been isolated (A. Isacchi et  
25       al, *supra*), and is homologous to the mouse three  
immunoglobulinlike-domain FGF receptor. In addition to the  
five forms of the FGF receptor, Southern blot analysis and the  
cloning of two related cDNAs, bek (H.H. Reid et al, *supra*; S.  
Kornbluth et al, *Mol Cell Biol* (1988) 8:5541-5544) and a bek-  
30       related molecule (H.H. Reid et al, *supra*), indicate that FGF  
receptors are members of a multigene family.

A number of researchers have recently reported expression of various FGF receptors. See R.J. Kaner et al, Science (1990) 248:1410-13; A. Mansukhani et al, Proc Nat Acad Sci USA (1990) 87:4378-82; C.A. Dionne et al, EMBO J (1990) 9:2685-92; and D.P. Mirda & L.T Williams, Clin Res (1990) 38:310A. However, the reported experiments in general do not disclose the expression of human FGF receptor in quantity sufficient for study.

In order to usefully study the binding of FGF analogs to the FGF receptor, one must have available sufficient quantities of active receptor for study. Further, the receptor must be in a useful form.

#### Disclosure of the Invention

A new human FGF receptor has now been cloned and expressed using cDNA obtained from a human liver cell line. The expression of high levels of the extracellular region of this FGF receptor in a baculovirus/insect cell system yields a high affinity FGF-binding protein that is active in radioreceptor assays, inhibits cell growth and that can be used to study the ligand-receptor interaction. Furthermore, four forms of the cDNAs that encode the FGF receptor have now been identified in several tissues and cell lines, suggesting there exists an extensive distribution of alternate forms that are generated by differential RNA splicing.

Thus, one aspect of the invention is a recombinant FGF receptor (rFGF-R), which is capable of binding aFGF and/or bFGF. Another aspect of the invention is a recombinant fragment of FGF-R comprising the extracellular domain (soluble FGF-R, or "sFGF-R"), which is capable of binding aFGF and/or bFGF.

Another aspect of the invention is a method for detecting FGF in a sample, by employing rFGF-R in a manner analogous to an anti-FGF antibody in any form of immunoassay. For example, one may detect FGF by providing a support comprising rFGF-R bound to a solid surface, contacting the support with a sample to be assayed for FGF, removing the portion of the sample which does not bind to the support, and detecting the presence of bound FGF on the support (e.g., by using a labeled anti-FGF antibody, by competition with labeled FGF, etc.).

Another aspect of the invention is a method for inhibiting the activity of FGF, using rFGF-R. Thus, rFGF-R may be used to inhibit FGF-mediated activities. For example, one method of the invention is the inhibition of FGF-dependent tumor growth by administering an effective amount of sFGF-R. Another method of the invention is the method of inhibiting angiogenesis (e.g., of a tumor) by administering an effective amount of sFGF-R. Another method of the invention is the method of inhibiting FGF-dependent cell growth *in vitro* by administering rFGF-R.

Another aspect of the invention is the use of rFGF-R to screen and identify compounds which mimic FGF binding. Compounds identified in this manner may be agonists or antagonists. Agonists are useful in situations in which FGF activity is beneficial, e.g., for acceleration of wound healing, nerve outgrowth, and the like. Antagonists are useful for inhibiting the activity of FGF, for example, to inhibit the growth of FGF-dependent malignancies, and the like. Compounds may be screened by providing a support having bound rFGF-R, contacting the support with a candidate compound, and detecting any compound bound to the support. Suitable compounds may also be used to block or inhibit binding by Herpes virus.

Brief Description of the Drawings

Figure 1 depicts a schematic diagram of the human FGF receptor cDNA (*flg 5*) and sequencing strategy. The translated regions are boxed, and various shaded domains are indicated:

5 S, signal peptide; 1-3, immunoglobulinlike-domains 1-3; ARR, acidic amino acid rich region; TM, transmembrane region; TK, tyrosine kinase domains. Potential Asn-linked glycosylation sites are also indicated (♦) as are the BglII (G) and EcoRI (E) restriction endonuclease sites. Although shown, the location  
10 of the most carboxyl-terminal consensus glycosylation site most likely precludes its use. Sequences were obtained by using M13 primers and specific internal primers. Arrows indicate the direction and extent of individual sequencing runs. The DNA sequence is in the Genbank and EMBL data bases, and accession  
15 numbers are available from these organizations.

Figure 2 depicts an amino acid sequence comparison of the six different human FGF receptor forms. Sequences have been aligned for maximum identity and those that differ or are deleted have been boxed. Various domains (abbreviations as in  
20 Fig. 1) and regions used for PCR primers (P1-P4) are indicated above sequence 1 (*flg 5*). The putative signal peptidase cleavage site is also indicated (↓). Sequence 2 was from A. Isacchi et al, *supra* and sequences 3-6 were from D.E. Johnson et al, *supra*.

25  
Modes of Carrying Out The Invention

A. Definitions

The term "FGF receptor" or "FGF-R" as used herein refers to the human FGF receptor or a fragment thereof capable  
30 of binding FGF in the presence of heparin, and having an amino acid sequence substantially as depicted in Figure 2. The term "rFGF-R" refers to active FGF-R prepared by recombinant means.

A preferred form of rFGF-R is soluble rFGF-R ("sFGF-R"), which is a truncated form obtained by expressing only the extracellular domain. It is surprisingly found that the truncated form retains its FGF-binding activity, and thus may be used to assay compounds for FGF-like binding activity or to bind actual FGF and thus inhibit its activity. The preferred sFGF-R of the invention is a 58 kDa glycoprotein which binds bFGF with a  $K_d$  of 2-5 nM.

The term "substantially pure" indicates a protein or composition that is essentially free of contaminants similar to the protein. In the present case, the normal contaminants associated with FGF-R predominately include human proteins. Thus, rFGF-R is substantially pure if it is essentially free of human proteins. "Essentially free" is determined by weight. In general, a composition containing 70% rFGF-R and  $\leq 30\%$  human proteins may be considered substantially pure. Preferably, the composition will be at least 80% rFGF-R, more preferably at least 90%, and most preferably  $\geq 95\%$  rFGF-R. The presence of dissimilar components does not affect the determination of purity, thus a composition containing 0.7 mg/mL rFGF-R in PBS will still be considered substantially pure if it contains  $\leq 0.3$  mg/mL other human proteins.

The term "effective amount" refers to an amount of rFGF-R sufficient to exhibit a detectable therapeutic effect.

The therapeutic effect may include, for example, without limitation, inhibiting the growth of undesired tissue or malignant cells, inhibiting the growth of FGF-dependent cells in the presence of cells not so constrained, inhibiting infection by HSV, and the like. The precise effective amount for a subject will depend upon the subject's size and health, the nature and severity of the condition to be treated, and the like. Thus, it is not possible to specify an exact effective

amount in advance. However, the effective amount for a given situation can be determined by routine experimentation based on the information provided herein.

5 The term "specific binding" indicates binding which defines a generally stoichiometric ligand-receptor relationship. Specific binding indicates a binding interaction having a low dissociation constant, which distinguishes specific binding from non-specific (background) binding.

10 "PCR" refers to the technique of polymerase chain reaction as described in Saiki, et al., Nature 324:163 (1986); U.S. Patent No. 4,683,195; and U.S. Patent No. 4,683,202.

#### B. General Method

15 The FGF-R may be cloned and expressed as described below, based on the disclosed PCR primer sequences. It is presently preferred to express rFGF-R using a baculovirus vector, see, e.g., commercially available kits from Invitrogen, San Diego CA ("MaxBac" kit), Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987).  
20 Although other expression systems are not excluded, see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, 1989 (bacterial expression); Barr et al., Yeast Genetic Engineering, Butterworths, Boston, MA, 1989 (yeast expression);  
25 U.S. Patent Nos. 4,399,216; 4,912,040; 4,740,461; 4,959,455 (these patents are incorporated herein by reference) (mammalian cell expression).

30 Using a baculovirus expression system, the protein is expressed as a glycoprotein in insect cells, and may easily be purified using lentil lectin chromatography. Active truncated forms of rFGF-R may be prepared by expressing only the extracellular binding domain, preferably aa<sub>1-374</sub>.

Immunoassay protocols may be based, for example, upon competition, direct reaction, or sandwich type assays. Protocols may also use solid supports, or may involve immunoprecipitation. Most assays involve the use of labeled antibody or ligand. The labels may be, for example, fluorescent, chemiluminescent, radioactive, dye molecules, or enzymes. Assays that amplify the signals from the probe are also known, for example, assays that utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

Typically, an assay for detecting FGF or FGF analogs will involve selecting and preparing the test sample, such as a biological sample, and then incubating it with the FGF-R under conditions that allow receptor-ligand complexes to form. Such conditions are well known in the art. In a heterogeneous format, the receptor is bound to a solid support to facilitate separation of the sample from the receptor after incubation. Examples of solid supports that can be used are nitrocellulose, in membrane or microtiter well form; polyvinylchloride, in sheets or microtiter wells; polystyrene latex, in beads or microtiter plates; polyvinylidene fluoride, known as Immobulon<sup>TM</sup>; diazotized paper; nylon membranes; activated beads; and Protein A beads. The solid support is typically washed after separating it from the test sample. In a homogeneous format, the test sample is incubated with a soluble form of the receptor in solution (e.g., sFGF-R), under conditions that will precipitate any receptor-ligand complexes that are formed, as is practiced in the art. The precipitated complexes are then separated from the test sample, for example, by centrifugation.

The complexes formed comprising FGF or FGF analogs in either the homogenous or heterogenous format can be detected by



any of a number of techniques. Depending on the format, the complexes can be detected with labeled antibodies against FGF-receptor, FGF, or FGF analogs; or labeled FGF-R or, if a competitive format is used, by measuring the amount of bound, labeled competing FGF or FGF analogs.

The use of enzyme-linked antibodies is one well-known method for detecting receptor-ligand complexes. This method depends upon conjugation of an enzyme to antibodies against FGF, FGF analogs, or FGF-R, and uses the bound enzyme activity as a quantitative label. Enzymes suitable for labeling are known in the art, and include, for example, horseradish peroxidase and urease. Enzyme activity, bound to the receptor-ligand complex, is measured by adding the specific enzyme substrate, and determining product formation or substrate utilization. For ease, the substrate can be chosen so that substrate utilization can be determined colorimetrically.

Kits suitable for FGF or FGF analog detection can contain the appropriate reagents, which may or may not be labeled, such as FGF-R, FGF, or FGF analogs, or antibodies directed against FGF-R, FGF, or FGF analogs in suitable containers; along with the remaining reagents and materials required for the conduct of the assay (e.g., wash buffers, detection means, such as labeled FGF or FGF analogs or labeled anti-FGF-R), as well as a suitable set of assay instructions.

It is convenient to use sFGF-R to assay compounds for FGF-like binding activity, and thus to identify compounds which may serve as agonists or antagonists. In a typical screening assay, sFGF-R is adsorbed onto a support (such as the wells of a microtiter plate), fixing with glutaraldehyde if necessary. Alternatively, the sFGF-R may be immobilized using a lectin, such as ConA. The support is then contacted with a solution containing the compound(s) in question, allowed to incubate,

and the remaining solution removed. After several washes, the plate is examined for the presence of bound compound. Bound compound may be detected by spectroscopic means (for example colorimetric or fluorometric means, depending on the characteristics of the compound), or by radioactive means if the compound has been so labeled. Alternatively, one may assay the compound for competition with labeled FGF. A large number of such assays can be performed and analyzed simultaneously, for example by conducting the experiments in an array (e.g., using a microtiter dish). In order to more completely model FGF, the compounds should be assayed for binding in the presence of heparin. It is theorized that both low affinity and high affinity FGF receptors are required for full FGF activity in vivo. It has now been found that FGF fails to bind the high affinity receptor with the same affinity in the absence of the low affinity receptor, but that the presence of sufficient heparin restores binding. Thus, one may completely model the FGF binding system in vitro using only sFGF-R and heparin. Compounds which exhibit a high affinity for sFGF-R may then be assayed for biological activity against FGF-R, or for inhibition of HSV infectivity, in an appropriate whole cell assay.

FGF is known to stimulate the growth and proliferation of many cell types, including normal cells of mesenchymal, epithelial or neural origin, and tumor cells, including melanoma. Some tumor types depend upon autocrine activity of FGF for proliferation. Accordingly, it is possible to employ rFGF-R to inhibit such proliferation in vivo or in vitro. In vivo, one may administer an effective amount of rFGF-R, preferably sFGF-R, to inhibit the undesirable growth of normal tissue (e.g., in scar formation, psoriasis, and other hyperplasias) or malignant tissue (as in the case of tumors,

carcinomas, and the like). As FGF may stimulate angiogenesis, administration of rFGF-R may be used, for example, to inhibit the vascularization of inoperable tumors.

HSV is believed to invade susceptible cells through the FGF receptor. Thus, one may inhibit HSV infection by administering sFGF-R to susceptible surfaces, for example the mucosal membranes. Such administration is preferably in the form of a lotion, ointment, salve, or aerosol.

Compositions of the invention for administration will generally include an effective amount of sFGF-R in addition to a pharmaceutically acceptable excipient. Suitable excipients include most carriers approved for oral or parenteral administration, including water, saline, Ringer's solution, Hank's solution, and solutions of glucose, lactose, dextrose, ethanol, glycerol, albumin, and the like. These compositions may optionally include stabilizers, antioxidants, antimicrobials, preservatives, buffering agents, surfactants, and other accessory additives. A presently preferred vehicle comprises about 1 mg/mL serum albumin in phosphate-buffered saline (PBS). A thorough discussion of suitable vehicles for parenteral administration may be found in E.W. Martin, "Remington's Pharmaceutical Sciences" (Mack Pub. Co., current edition).

The precise dosage necessary will vary with the age, size, and condition of the subject, the nature and severity of the disorder to be treated, and the like: thus, a precise effective amount cannot be specified in advance. However, appropriate amounts may be determined by routine experimentation with animal models. In general terms, an effective dose sFGF-R will range from about 10  $\mu$ g/Kg to about 5 mg/Kg.

C. Examples

The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.

Example 1

(Procedures)

Materials:

Human basic FGF was produced in yeast, as described by P.J. Barr et al, J Biol Chem (1988) 263:16471-16478. Enzymes for molecular biology were obtained from Boehringer Mannheim, New England Biolabs and Pharmacia. The  $\lambda$ ZAP cDNA cloning kit was obtained from Stratagene. The PCR amplification kit was from Perkin Elmer Cetus. Radiochemicals were obtained from Amersham or New England Nuclear. Lentil lectin Sepharose® 4B and methyl- $\alpha$ -D-mannopyranoside were obtained from Sigma. Human liver poly (A)<sup>+</sup> RNA was obtained from Clontech (Palo Alto, CA) and human osteosarcoma tissue was a gift from Dr. Marshall Urist (University of California, Los Angeles).

Hep G2 (ATCC No. HB 8065), a human hepatoma cell line; 293, a human embryonic kidney cell line (ATCC No. CRL 1573); and *Spodoptera frugiperda* clone 9 (Sf9) an insect cell line, were obtained from the American Type Culture Collection (Rockville, MD). Hep G2 and 293 cells were grown to subconfluency in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin at 37°C in 5% CO<sub>2</sub>. Sf9 cells were adapted to grow in Excell-400 serum free medium (J.R. Scientific). Procedures for culturing and subculturing the cells, transfections and production of high titer viral stocks were

performed as described (M.D. Summers & G.E. Smith, (1987) A Manual of Methods of Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agriculture Experiment Station Bulletin No. 1555). Wild type *Autographa californica* nuclear polyhedrosis virus (AcMNPV) viral DNA and transfer plasmid pAc373 were a gift of Dr. Max Summers (Texas A&M University).

Example 2

(Expression of EC-FGF Receptor)

10 Oligonucleotide Synthesis:

Oligonucleotide adapters, probes and sequencing primers were synthesized by the phosphoramidite method using Applied Biosystems (Foster City, CA) model 380A and 380B synthesizers, purified by polyacrylamide gel electrophoresis and desalted on SEP-PAK C<sub>18</sub> cartridges (Waters, Milford, MA). The oligonucleotide probes used for screening the cDNA library were complementary to nucleotides 1-30 (5'-A-TAACGGACCTTGTAGCCTCCAATTCTGTG-3') and nucleotides 1840-1869 (5'-GCGGCGTTTGAGTCCGCCATTGGCAAGCTG-3') of the published *flg* nucleic acid sequence (M. Ruta et al, *supra*). The two PCR primers used to amplify the extracellular region of the FGF receptor (*flg5*) cDNA consisted of a sense primer, P4 (5'-CCAACCTCTAGAGGATCCACTGGGATGTGGAGCTGGAAGTGC-3') containing the ribosome binding site plus amino acids 1-6 of *flg* 5 and an antisense primer, P3 (5'-GTAAGCGGCCGCGGATCCTTACTACTCCAGGTACAGG-GGCGA-3') containing amino acids 369-374 of *flg5* and directly followed by a termination codon. Both primers contain BamHI sites to facilitate cloning into pAc373. Two additional PCR primers were used to identify two and three immunoglobulinlike domain FGF receptors in various tissues. They were a sense primer, P1 (5'-CCATTTGGATCCGTCACAGCCACACTCTGCACCGCT-3') encoding amino acids 14 to 21 of *flg* 5 and an antisense primer

P2 (5'-CCATTGTCGACTTCCATCTTTTCTGGGGATGTCCA-3') encoding the complement of amino acids 154 to 161 of *flg* 5. The primers contain BamHI and SalI sites to facilitate cloning into M13 sequencing plasmids.

5 RNA Isolation and Construction and Screening of the cDNA Library:

10 RNA was isolated by the guanidinium thiocyanate method (J.M. Chirgwin et al, Biochem (1979) 18:5294-5299) with modifications (G.J. Freeman et al, Proc Natl Acad Sci USA (1983) 80:4094-4098). Poly(A)<sup>+</sup> RNA was purified by a single fractionation over oligo(dT) cellulose (H. Aviv & P. Leder, Proc Natl Acad Sci USA (1972) 69:1408-1412). The construction and screening of the Hep G2 library in λZAP has been described (J. Zapf et al, J Biol Chem (1990) 265:14892-14898). The  
15 probes were labeled with T<sub>4</sub> polynucleotide kinase and [γ-<sup>32</sup>P]-ATP (J. Sambrook et al, (1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), 2nd Ed) to a specific activity of 1-2 × 10<sup>8</sup> cpm/mg. Approximately 600,000 recombinant phages from the Hep G2 cDNA  
20 library were screened on duplicate nitrocellulose filters (Millipore, HATF 137), with two *flg* oligonucleotide probes. Areas of plaques that hybridized to both probes were further purified.

Plasmid Isolation, Subcloning and Sequencing:

25 Bluescript SK(-) plasmids containing the putative *flg* cDNA inserts were released from λZAP by the M13 rescue/excision protocol described by the supplier (Stratagene). Plasmid DNA was isolated by the alkaline lysis method (J. Sambrook et al, *supra*). The cDNA inserts containing the putative *flg* sequence  
30 were excised from the Bluescript SK(-) vector by BglII or EcoRI digestion and fractionated by agarose gel electrophoresis. Inserts were excised from the gel and passively eluted for 16 h

with gentle shaking in 10 mM Tris-hydrochloride, pH 7.5, 1 mM EDTA (TE), purified on elutip-D columns (Schleicher and Schuell) and subcloned into M13 sequencing vectors (C. Yanisch-Perron et al, Gene (1985) 33:103-119). PCR-amplified DNA was  
5 similarly purified. DNA sequencing was performed by the dideoxy chain termination method (F. Sanger et al, Proc Natl Acad Sci USA (1977) 74:5463-5467) using M13 primers as well as specific internal primers. Ambiguous regions were resolved using 7-deaza-2'-deoxyguanosine-5'-triphosphate (P.J. Barr et  
10 al, Biotechniques (1986) 4:428-432) and Sequenase (US Biochemicals).

To isolate full length FGF receptor encoded cDNAs, 600,000 recombinants from a  $\lambda$ ZAP-human hepatoma cell line (Hep G2) cDNA library were screened with oligonucleotide probes  
15 derived from the 5'- and 3'-ends of a partial *flg* cDNA (M. Ruta et al, *supra*). Six clones were identified that hybridized to both probes. BglIII restriction endonuclease digestion of the cDNA inserts and gel analysis suggested that three of the six clones contained the complete coding sequence. Four BglIII  
20 fragments of 1.6, 1.1, 0.6, and 0.55 Kb and two EcoRI fragments of 2.7 and 1.2 Kb were identified in the longest cDNA clone, *flg* 5 (Fig. 1). BglIII and EcoRI sites are also present in the flanking adapters that were used to make the cDNA library. The BglIII and EcoRI fragments of *flg* 5 cDNA were isolated, cloned  
25 into M13 mp19 and sequenced. A detailed sequencing strategy is shown in Fig 1. The *flg* 5 cDNA encodes a protein of 820 amino acids and is flanked by 671 and 753 nucleotides of 5'- and 3'-untranslated regions, respectively. The encoded protein revealed a structure that included a signal peptide, three  
30 extracellular immunoglobulinlike domains, an acidic amino acid-rich region, a transmembrane domain and a split intracellular tyrosine kinase domain. These domains have been identified

previously on the chicken (P.L. Lee et al, supra), the mouse (H.H. Reid et al, supra) and most recently, several human FGF receptors deduced from cDNA sequences (A. Isacchi et al, supra; D.E. Johnson et al, supra). The encoded receptor also contains  
5 eight consensus N-linked glycosylation sites in the extracellular region and one in the cytoplasmic tyrosine kinase domain.

The amino acid sequence encoded by flg 5 cDNA is shown in Fig. 2 (top row). For comparison, five other  
10 previously identified forms of the human FGF receptors are shown (A. Isacchi et al, supra; D.E. Johnson et al, supra) and are aligned for maximum amino acid sequence identity. The identified structural domains are indicated above the flg 5 sequence, as are regions corresponding to the PCR primers. The  
15 putative signal peptidase cleavage site (G. von Heijne, Nuc Acids Res (1986) 14:4683-4690) after Ala<sub>21</sub> is indicated (↓). Differences or deletions of amino acids are boxed. The three most notable differences between the six FGF receptors are: i) a large deletion near the N-terminus in FGF receptors 3-6  
20 (aa<sub>31-119</sub>) that spans the entire first immunoglobulinlike domain; ii) truncation of receptors 5 and 6, which differ from the other FGF receptors in their carboxyl terminal amino acids (aa<sub>221-300</sub> and aa<sub>223-302</sub> respectively), with consequent deletion of their transmembrane and cytoplasmic domains; and iii)  
25 deletion of amino acids 148 and 149 in FGF receptors 1, 3 and 5. Other differences in FGF receptor-3 (aa<sub>101</sub>) and FGF receptor-2 (aa<sub>817</sub>) are also noted. The partial flg sequence (15) is not shown, but has an N-terminal amino acid corresponding to position 198 of FGF receptor-1. Accordingly,  
30 it may be encoded by the cDNAs of FGF receptors 1, 2, 3 or 4. It is important to note however, that the flg sequence displays a difference from FGF receptors 1-4 in the tyrosine kinase



domain at aa<sub>670-674</sub>, due to three nucleic acid deletions flanking this region that results in a limited frame shift.

PCR Amplification:

Amplification reactions were performed according to the supplier of the PCR kit (Perkin Elmer Cetus). PCR primers and template were at a final concentration of 1 mM and 0.1-0.5 mg/mL, respectively. The cDNA encoding *flg5* was used as a template DNA for the construction of EC-FGF receptor in pAc373. For expression studies, template DNA was reverse transcribed from mRNA as described (J. Zapf et al, supra). 30 cycles of PCR were performed using a Perkin Elmer Cetus DNA thermal cycler. Each cycle consisted of a 94°C, 1 min denaturation step; a 55°C, 2 min annealing step; and a 72°C, 3 min extension step. The extension step in the last cycle was 7 min.

Construction of Recombinant EC-FGF Receptor Virus:

The PCR amplified DNA fragment encoding the extracellular domain of the FGF receptor was digested with BamH1, gel purified and ligated to BamH1 cut, calf intestinal phosphatase-treated pAc373. Recombinant plasmids were analyzed for EC-FGF receptor cDNAs inserted in the correct orientation by restriction endonuclease digestion and agarose gel electrophoresis.

The recombinant plasmid was cotransfected with wild-type AcMNPV viral DNA into Sf9 cells by the calcium phosphate transfection procedure (M.D. Summers & G.E. Smith, supra). Recombinant viruses were identified in the first round of plaque screening by hybridization with *flg 5* cDNA that was <sup>32</sup>P-labeled by replacement synthesis (J. Sambrook et al, supra).

The recombinant viruses were further purified by visual screening for the occlusion negative phenotype in two additional rounds.

5 The recombinant baculovirus that expressed EC-FGF  
receptor was constructed by ligating PCR-amplified DNA encoding  
amino acids 1-374 of the *flg 5* cDNA into the BamH1 site of the  
baculovirus transfer vector pAc373. The PCR primers contained  
10 flanking BamH1 sites to facilitate cloning. In addition, the  
5' sense primer (P4) contained, directly upstream from the  
initiation codon, the -1 to -5 nucleotides of the *flg 5* cDNA  
sequence that are implicated in ribosome binding (M. Kozak, Nuc  
Acids Res (1984) 12:857-87239). The 3'-antisense primer (P3)  
15 contained two termination codons TAG and TAA directly after  
amino acid 374. Co-transfection of Sf9 cells with AcMNPV viral  
DNA and the recombinant construct (pAc373-EC-FGF receptor) by  
the calcium phosphate method (M.D. Summers & G.E. Smith, *supra*)  
generated recombinant baculovirus that were subsequently  
20 purified by plaque hybridization and visual screening.

Expression and Purification of EC-FGF Receptor:

Sf9 cells were seeded in T-150 flasks at  $5 \times 10^7$   
cells/flask for small scale production of EC-FGF receptor.  
After 2 hr, the cells were infected with recombinant virus and  
25 incubated for 68-72 hrs. For larger scale production of EC-FGF  
receptor, Sf9 cells were infected with recombinant virus,  
incubated for 1 hr at 25°C, and then incubated in 3L spinner  
flasks at  $3 \times 10^6$  cells/ml for 72-97 hrs. The conditioned  
medium from the above cultures were centrifuged for 30 min. at  
30 14,000 xg at 4°C to partially clarify the recombinant virus.  
An aliquot of the supernatant was analyzed for EC-FGF receptor  
by 15% trichloroacetic acid precipitation, denaturing SDS-  
polyacrylamide gel electrophoresis (PAGE) (U.K. Laemmli, *Nature*  
(1970) 227:680-685) and visualization by Coomassie blue  
staining.

To further purify the EC-FGF receptor, the clarified  
supernatant was adjusted to 25 mM Hepes, pH 7.3, and loaded

onto a lentil lectin Sepharose® 4B column equilibrated with 150 mM NaCl, 25 mM Hepes, pH 7.3, 1 mM CaCl<sub>2</sub> and 1 mM MnCl<sub>2</sub>. The column was washed in this equilibration buffer until no protein could be detected (OD<sub>280</sub> ≈ 0) in the flow-through. The EC-FGF receptor was then eluted with 10% methyl- $\alpha$ -D-mannopyranoside, 25 mM Hepes, pH 7.3. Peak fractions were pooled, concentrated (Centricon 30) and stored in 10 mM Tris, pH 7.0, at -80°C. Aliquots from the various stages of purification were analyzed by SDS-PAGE (U.K. Laemmli, *supra*) and visualized by Coomassie blue staining.

To analyze EC-FGF receptor expression by the recombinant EC-FGF receptor-containing baculoviruses, Sf9 cells were infected with either wild type AcMNPV or EC-FGF receptor-AcMNPV. After 68 hours of incubation, proteins in the supernatant were precipitated and analyzed by SDS-PAGE and Coomassie blue staining. The resulting gel showed that the most intensely stained protein band in the supernatant ( $M_r$  = 58,000) is present only in the EC-FGF receptor-AcMNPV-infected cells and is not in the AcMNPV-infected cells, suggesting that this protein is the EC-FGF receptor. Six recombinant EC-FGF receptor-containing baculoviruses were analyzed for EC-FGF receptor expression in Sf9 cells. The level of EC-FGF receptor expression was essentially identical.

Analysis of EC-FGF Receptor Oligosaccharides:

Oligosaccharides contained in the purified EC-FGF receptor were analyzed by endoglycolytic cleavage with N-glycanase (Genzyme, Boston) according to the supplier's specifications. The products were analyzed by SDS-PAGE (U.K. Laemmli, *supra*) and visualized by Coomassie blue staining. The expected  $M_r$  for an unmodified EC-FGF receptor is 74,000, suggesting that post-translational modification of the receptor occurs in insect cells. There are eight potential N-

glycosylation sites in the extracellular region of the FGF receptor to which oligosaccharides may be attached. To determine if N-linked oligosaccharides were present and contributed to the apparent  $M_r$  of the EC-FGF, the molecule was digested with N-glycanase. Digestion of EC-FGF receptor reduced the apparent  $M_r$  from 58,000 to 52,000, indicating that oligosaccharides were attached to the receptor through asparagine residues. In further support of this result, the EC-FGF receptor was purified by lentil lectin affinity chromatography.

### Example 3

(FGF Receptor Binding and Activity Assays)

#### Radioreceptor assay:

The effects of the EC-FGF receptor on the binding of radioiodinated basic FGF to its receptor was examined using a radioreceptor assay as described in the art. Briefly, baby hamster kidney cells were maintained in Hepes (25 mM) buffered DMEM supplemented with 5% calf serum and antibiotics and were grown to sub-confluence in 24-well dishes. The cells were washed twice with phosphate buffered saline and incubated for 3 hours at 4°C with the indicated concentrations of the peptides and 1 ng (100,000 cpm) of labelled basic FGF in 300  $\mu$ L of DMEM containing 0.1% gelatin. The medium was aspirated and the cells washed twice with 0.5 mL PBS and twice with 0.5 mL of PBS containing 2 M NaCl. The amount of  $^{125}$ I-FGF bound to the high affinity receptor was determined by quantitating the amount of radioactivity in the cell lysate obtained with 0.1% Triton® X-100 in PBS, pH 8.4.

#### Mitogenesis assay:

The effects of the peptides on mitogenesis was determined using Swiss 3T3 fibroblasts as described. Briefly,

cells were plated at a concentration of 20,000 cells/well in 96 microwells and grown for two days in Hepes (25 mM) buffered DMEM containing 10% fetal calf serum and antibiotics. On the third day, the cells were washed twice with DMEM with no additives and the cells synchronized by a further incubation for two days in 0.5% fetal calf serum. At the time of assay, the test substances (basic FGF, EC-FGFR or both together) were added directly to the cells in 10  $\mu$ L of DMEM supplemented with 0.1% BSA. Eighteen hours later, 1  $\mu$ Ci of  $^3$ H-thymidine was added to the cells, and 24 hours after the addition of the peptides, the media was aspirated, the cells washed with PBS and the proteins precipitated with 50% trichloroacetic acid. After three washes, the cells were solubilized overnight with 1 N NaOH and the amount of radioactivity incorporated into DNA was determined by scintillation counting.

Cell Proliferation Assays:

The EC-FGF receptor was tested for its ability to inhibit basic FGF stimulated adrenal capillary endothelial (ACE) cell proliferation. Aliquots of receptor preparation were added to ACE cells and four days later, the cell number was established using a Coulter particle counter. For comparison purposes, 2 ng/ml of recombinant human basic FGF increased cell proliferation from  $27,500 \pm 2,100$  cells/well to  $133,300 \pm 1,800$  cells/well.

Receptor dependent tyrosine phosphorylation:

Swiss 3T3 cells were treated at 37°C for 5 minutes with no additives or with basic FGF (15 ng/mL), EC-FGF receptor (10 mg/mL) or basic FGF (15 ng/mL) and EC-FGF (10 mg/mL) added together. The cells were then harvested in a 2.5x Laemmli's buffer, the proteins separated on 8% polyacrylamide SDS-PAGE gels and the presence of tyrosine phosphorylated proteins

examined by Western blotting with a specific anti-phosphotyrosine antibody.

The FGF binding properties of EC-FGF receptor was determined using a soluble binding assay (adapted from the assay described by J.E. Robinson et al, J Immunol Meth (1990) 132:63-71). EC-FGF receptor, attached to concanavalin A coated plastic wells, was incubated with  $^{125}\text{I}$ -bFGF and increasing concentrations of bFGF. Scatchard analysis of  $^{125}\text{I}$ -FGF binding indicated a  $K_d$  of less than 5nM. An completely accurate  $K_d$  determination was not possible due to the non-specific binding of  $^{125}\text{I}$ -FGF. Several blocking agents included in the assays, such as BSA, gelatin and heparan sulfate, were ineffective at blocking the non-specific binding of  $^{125}\text{I}$ -FGF at low concentrations of  $^{125}\text{I}$ -FGF.

The biological activity of the EC-FGF receptor was tested in several additional assay systems. First, the addition of EC-FGF receptor to endothelial cells in culture was shown to inhibit the proliferative effect of basic FGF. Because this cell type is known to synthesize basic FGF, it was suspected that the recombinant receptor might inhibit basal endothelial cell growth. As predicted, the expressed EC-FGF receptor can inhibit basal cell proliferation. Specificity of this effect was studied by incubating various cell types, that do not synthesize basic FGF, with the EC-FGF receptor. No effects were observed on BHK cells, A431 cells or on CHO cells. As expected, however, the addition of EC-FGF receptor to 3T3 cells inhibited the mitogenic response to basic FGF.

Furthermore, it was observed that the EC-FGF receptor inhibited the growth of melanoma cells, a cell type previously shown to be dependent on the autocrine production of basic FGF.

To establish that the FGF/EC-FGF receptor complex did not recognize the basic FGF receptor, two experiments were

performed. First, the addition of the EC-FGF receptor preparation to BHK cells during the radioreceptor assay prevented the binding of  $^{125}\text{I}$ -basic FGF to its receptor indicating that it binds basic FGF. The binding of  $^{125}\text{I}$ -basic FGF to its low affinity receptor was also inhibited. Secondly, basic FGF fails to activate the tyrosine phosphorylation of either its cell membrane receptor or the characteristic 90-kDa substrate identified by Coughlin et al, J Biol Chem (1988) 263:988-993 when incubated in the presence of EC-FGF receptor.

#### Example 4

##### (Alternate Receptor Forms)

To determine whether multiple forms of the FGF receptor mRNAs are expressed in a single tissue or cell type, PCR was performed using mRNA isolated from human liver and osteosarcoma tissue as well as from the hepatoma cell line Hep G2 and the embryonic kidney cell line, 293. For these experiments, we used primers derived from the nucleic acid sequence encoding amino acids 14 to 21 and 154 to 160 of the flg 5 cDNA (P1 and P2, Fig. 2). These primers can detect either the two or three immunoglobulinlike-domain transcripts and should yield a 184 bp or 441 bp PCR-generated DNA product, respectively. Additionally, deletion variants at amino acid positions 148 and 149 can be readily identified by DNA sequence analysis of the PCR products. The truncated FGF receptors 5 and 6 shown (Fig. 2), are not distinguished by the primers selected.

Acrylamide gel analysis of the PCR products revealed DNA fragments of the expected size in all four tissues. DNA sequence analysis of the fragments revealed sequences that were identical, between the PCR primers, to the four forms of the FGF receptor shown in Fig. 2 (FGF receptor 1-4). Several

additional DNA fragments of approximately 280 bp and 550 bp were observed in all four PCR reactions. These PCR products were sequenced and shown to encode sequences unrelated to the FGF receptor. Thus, at least four forms of the FGF receptor are expressed in the tissues and cell lines examined. Taken together with the previous findings, these results indicate that multiple forms of FGF receptor mRNA are expressed in a wide variety of cell types and that as many as four forms of the receptor may be present on the surface of a cell type. Whether these forms are coexpressed in single cells remains to be determined.

Sequencing of the PCR fragments, identified an additional form of FGF receptor RNA that contained an intervening sequence. This form of the FGF receptor RNA most likely represents incompletely spliced heteronuclear RNA since a splicing event has already deleted the immunoglobulinlike 1 domain (aa<sub>31-119</sub>). Interruption of the encoded amino acid sequence occurred at Pro<sub>150</sub> (vertical lines A and C) and was separated by 248 nucleotides. This intervening region contains the dinucleotides GT and AG at its 5' and 3' ends, respectively, and is most likely derived from an intron.

The presence of an intron at aa<sub>150</sub> suggested that an alternate splice donor site 2 amino acids upstream from 150 could generate the variant forms of the FGF receptor lacking amino acids 148 and 149. Indeed, six bases upstream (vertical line B) from amino acid 150, there is an acceptable splice donor site that could substitute for the downstream site and that would generate an in-frame deletion of amino acids 148 and 149. Thus, both the two and three immunoglobulinlike forms of the FGF receptor as well as the variant forms at amino acids 148 and 149 can be explained by alternate splicing.



WHAT IS CLAIMED:

1. A substantially pure human fibroblast growth factor receptor capable of binding human FGF.

2. The fibroblast growth factor receptor of claim 1, wherein said fibroblast growth factor receptor has substantially the amino acid sequence shown in Figure 2.

3. A substantially pure recombinant human fibroblast growth factor receptor (rFGF-R) capable of binding FGF.

4. The rFGF-R of claim 3 having substantially the amino acid sequence shown in Figure 2.

5. The rFGF-R of claim 3 comprising amino acids 1-374 of the amino acid sequence shown in Figure 2.

6. A method for inhibiting the activity of FGF on a cell, said method comprising providing an effective amount of FGF-R to the cell.

7. The method of claim 6, wherein said cell is cultivated *in vitro*.

8. The method of claim 6 wherein said FGF-R is provided by administration to a mammal.

9. The method of claim 6, wherein said FGF-R is recombinant.

10. The method of claim 9, wherein said recombinant FGF-R is soluble and comprises amino acids 1-374 of the amino acid sequence shown in Figure 2.

5 11. The method of claim 6, wherein said cell is an FGF-dependent tumor cell.

12. The method of claim 6, wherein said activity of FGF on a cell is angiogenesis.

10 13. A method for inhibiting infection of a mammal by a Herpes virus, comprising:  
administering to said mammal an effective amount of rFGF-R.

15 14. The method of claim 13, wherein said rFGF-R is sFGF-R.

20 15. The method of claim 14, wherein said sFGF-R is sFGF-R<sub>1-374</sub>.

16. The method of claim 13, wherein said rFGF-R is administered to the mucosal membranes of said mammal.

25 17. The method of claim 16, wherein said rFGF-R is administered as an aerosol.

18. A method for identifying a compound capable of mimicking the binding of FGF to its receptor, said method comprising:

providing a rFGF-R;

5 contacting said rFGF-R with a sample containing said compound; and

detecting the occurrence of specific binding between said compound and rFGF-R.

10 19. The method of claim 18, wherein said rFGF-R is bound to a solid support.

20. The method of claim 18, wherein specific binding is determined by competition with labeled FGF.

15 21. The method of claim 18, wherein specific binding is determined spectroscopically.

ABSTRACT OF THE DISCLOSURE

5 A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.



1	MWSWKCLFWAVLVTATLCT	SPTLPEQAQPWGAPVEVESFLVHFGDL	RLRDDVQSIINWLRDGVQLAE	75
2	MWSWKCLFWAVLVTAT	SPTLPEQAQPWGAPVEVESFLVHFGD	LRDDVQSIINWLRDGVQLAE	75
3	MWSWKCLFWAVLVTAT	SPTLPEQ		30
4	MWSWKCLFWAVLVTATLCTARPSPTLPEQ			30
5	MWSWKCLFWAVLVTATLCTARPSPTLPEQ			30
6	MWSWKCLFWAVLVTATLCTARPSPTLPEQ			30
ARR				
	SNRTRITGEEVEVDSPADSGLYACVTSSPSGSDTTYFSVNVSDALPSS	EDDDDDDDSSSEKETDNTKPN		148
	SNRTRITGEEVEVDSPADSGLYACVTSSPSGSDTTYFSVNVSDALPSS	EDDDDDDDSSSEKETDNTKPN		150
		DALPSS	EDDDDDSSSEKETDNTKPN	59
		DALPSS	EDDDDDSSSEKETDNTKPN	61
		DALPSS	EDDDDDSSSEKETDNTKPN	59
		DALPSS	EDDDDDSSSEKETDNTKPN	61
2				
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 223
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 225
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 134
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 136
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 134
	VAPYNTSPKMEKKLHAPPAAKTVKFKCPS	SGTNPNTLRWLKNGKEFKPDHRIGGYKVRATWSI	IMDSVVP	SDK 136
P2				
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	298
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	300
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	209
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	211
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	209
	GNYTCIVENEYGSINHTYQLDVVERS	PHRPILQAGLPANKTVALG	SNVEFMCKVYSDPQPHIQWLKHIEVNGSKI	211
P3				
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
	GPDNLPPYQILKTAGVNTTDKEMEVLHLRNVS	FEDAGEYTCLAGNSIGLSHSAWLT	LEALEERP	PAVMTSP
IM				
	IIIIYCTGAFLISCMVGSVIVYKMKSGTKKSD	FHSQMAVHKAKSIPLRRQVTVSADSSAS	MNSGVLLVRPSRLS	448
	IIIIYCTGAFLISCMVGSVIVYKMKSGTKKSD	FHSQMAVHKAKSIPLRRQVTVSADSSAS	MNSGVLLVRPSRLS	450
	IIIIYCTGAFLISCMVGSVIVYKMKSGTKKSD	FHSQMAVHKAKSIPLRRQVTVSADSSAS	MNSGVLLVRPSRLS	359
	IIIIYCTGAFLISCMVGSVIVYKMKSGTKKSD	FHSQMAVHKAKSIPLRRQVTVSADSSAS	MNSGVLLVRPSRLS	361
	EVSWEQR	GMGGAGL		300
	EVSWEQR	GMGGAGL		302
TK				
	SSGTPLAGVSEYELPEDPRWELPRDRLVLGKPL	LGEGCFGQVVLAE	AIGLDKDKPNRVTKVAVKMLKSDATEKDL	523
	SSGTPLAGVSEYELPEDPRWELPRDRLVLGKPL	LGEGCFGQVVLAE	AIGLDKDKPNRVTKVAVKMLKSDATEKDL	525
	SSGTPLAGVSEYELPEDPRWELPRDRLVLGKPL	LGEGCFGQVVLAE	AIGLDKDKPNRVTKVAVKMLKSDATEKDL	434
	SSGTPLAGVSEYELPEDPRWELPRDRLVLGKPL	LGEGCFGQVVLAE	AIGLDKDKPNRVTKVAVKMLKSDATEKDL	436
	SDLISEM	MMKIGKHKNIINLLGACTQDGP	LYVIVEYASKGNLREYLQARRPPGLECYNPSHNPEEQLSSKDL	598
	SDLISEM	MMKIGKHKNIINLLGACTQDGP	LYVIVEYASKGNLREYLQARRPPGLECYNPSHNPEEQLSSKDL	600
	SDLISEM	MMKIGKHKNIINLLGACTQDGP	LYVIVEYASKGNLREYLQARRPPGLECYNPSHNPEEQLSSKDL	509
	SDLISEM	MMKIGKHKNIINLLGACTQDGP	LYVIVEYASKGNLREYLQARRPPGLECYNPSHNPEEQLSSKDL	511
	VSCAYQVARGMEYLASKKCIHRDLAARNVL	VTEDNMVKIADFGLARDIHHIDYKXTTNGRLPVKWM	APALFDR	673
	VSCAYQVARGMEYLASKKCIHRDLAARNVL	VTEDNMVKIADFGLARDIHHIDYKXTTNGRLPVKWM	APALFDR	675
	VSCAYQVARGMEYLASKKCIHRDLAARNVL	VTEDNMVKIADFGLARDIHHIDYKXTTNGRLPVKWM	APALFDR	584
	VSCAYQVARGMEYLASKKCIHRDLAARNVL	VTEDNMVKIADFGLARDIHHIDYKXTTNGRLPVKWM	APALFDR	586
TK				
	IYTHQSDVWSFGVLLWEIFTLGGSPYPGVP	VEELFKLLKEGHRMDKPSNCTNELYMMRDCW	HAVPSQRPTFKQL	748
	IYTHQSDVWSFGVLLWEIFTLGGSPYPGVP	VEELFKLLKEGHRMDKPSNCTNELYMMRDCW	HAVPSQRPTFKQL	750
	IYTHQSDVWSFGVLLWEIFTLGGSPYPGVP	VEELFKLLKEGHRMDKPSNCTNELYMMRDCW	HAVPSQRPTFKQL	659
	IYTHQSDVWSFGVLLWEIFTLGGSPYPGVP	VEELFKLLKEGHRMDKPSNCTNELYMMRDCW	HAVPSQRPTFKQL	661
	VEDLDRIVALTSNQEYLDLSMPLDQYSP	SFPDTRSSSTCSSGDSVFSHEPLPEEPCLPRHPA	AQLANGGLKRR	820
	VEDLDRIVALTSNQEYLDLSMPLDQYSP	SFPDTRSSSTCSSGDSVFSHEPLPEEPCLPRHPA	AQLANGGLKRR	822
	VEDLDRIVALTSNQEYLDLSMPLDQYSP	SFPDTRSSSTCSSGDSVFSHEPLPEEPCLPRHPA	AQLANGGLKRR	731
	VEDLDRIVALTSNQEYLDLSMPLDQYSP	SFPDTRSSSTCSSGDSVFSHEPLPEEPCLPRHPA	AQLANGGLKRR	733

Figure 2

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

EXPRESSION AND USE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR

the specification of which (check one)        is attached hereto X was filed on January 11, 1991 as Application Serial No. 07/640,029 and was amended on        (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) Number	Country	Day/Month/Year Filed	Priority Claimed Yes No
--	---------	----------------------	----------------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status Patented, Pending, Abandoned
---------------------------	-------------	--

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Michael C. Keifer

Inventor's signature Michael C. Keifer Date 6-10-91

Residence Clayton, California

Citizenship U.S.A.

Post Office Address 401 Wright Court, Clayton, CA 94517

Full name of sole or second inventor Pablo D.T. Valenzuela

Inventor's signature Pablo D.T. Valenzuela Date 6-10-91

Residence Berkeley, California

Citizenship Chile

Post Office Address 2919 Avalon Avenue, Berkeley, CA 94705

Full name of sole or third inventor Philip J. Barr

Inventor's signature Philip J. Barr Date 6/10/91

Residence Oakland, California

Citizenship United Kingdom

Post Office Address 67 Bay Forest Drive, Oakland, CA 94611



# SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Kiefer, Michael C.  
Pablo, Valenzuela D.T.  
Philip, Barr J.
- (ii) TITLE OF INVENTION: Expression and Use of Human Fibroblast Receptor
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Chiron Corporation
  - (B) STREET: 4560 Horton Street
  - (C) CITY: Emeryville
  - (D) STATE: CA
  - (E) COUNTRY: USA
  - (F) ZIP: 94608
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/439,992
  - (B) FILING DATE: 12-MAY-1995
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Chung, Ling-Fong
  - (B) REGISTRATION NUMBER: 36,482
  - (C) REFERENCE/DOCKET NUMBER: 0165.004
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 510-923-2704
  - (B) TELEFAX: (510) 655-3542

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 820 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
 

Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala			
1	5	10	15
Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Ala Gln			
20	25	30	
Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly			
35	40	45	

Asp Leu Leu Gln Leu Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile  
 50 55 60  
 Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg  
 65 70 75 80  
 Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser  
 85 90 95  
 Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr  
 100 105 110  
 Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp  
 115 120 125  
 Asp Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr  
 130 135 140  
 Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu  
 145 150 155 160  
 Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys  
 165 170 175  
 Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly  
 180 185 190  
 Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr  
 195 200 205  
 Ala Thr Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly  
 210 215 220  
 Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr  
 225 230 235 240  
 Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln  
 245 250 255  
 Ala Gly Leu Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu  
 260 265 270  
 Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu  
 275 280 285  
 Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro  
 290 295 300  
 Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn Thr Thr Asp Lys Glu  
 305 310 315 320  
 Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu  
 325 330 335  
 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala  
 340 345 350  
 Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg Pro Ala Val Met Thr  
 355 360 365  
 Ser Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala Phe Leu  
 370 375 380  
 Ile Ser Cys Met Val Gly Ser Val Ile Val Tyr Lys Met Lys Ser Gly  
 385 390 395 400  
 Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His Lys Leu Ala

Lys	Ser	Ile	Pro	Leu	Arg	Arg	Gln	Val	Thr	Val	Ser	Ala	Asp	Ser	Ser
			420					425					430		
Ala	Ser	Met	Asn	Ser	Gly	Val	Leu	Leu	Val	Arg	Pro	Ser	Arg	Leu	Ser
		435					440					445			
Ser	Ser	Gly	Thr	Pro	Met	Leu	Ala	Gly	Val	Ser	Glu	Tyr	Glu	Leu	Pro
		450				455					460				
Glu	Asp	Pro	Arg	Trp	Glu	Leu	Pro	Arg	Asp	Arg	Leu	Val	Leu	Gly	Lys
465					470				475						480
Pro	Leu	Gly	Glu	Gly	Cys	Phe	Gly	Gln	Val	Val	Leu	Ala	Glu	Ala	Ile
				485					490						495
Gly	Leu	Asp	Lys	Asp	Lys	Pro	Asn	Arg	Val	Thr	Lys	Val	Ala	Val	Lys
			500					505					510		
Met	Leu	Lys	Ser	Asp	Ala	Thr	Glu	Lys	Asp	Leu	Ser	Asp	Leu	Ile	Ser
		515					520					525			
Glu	Met	Glu	Met	Met	Lys	Met	Ile	Gly	Lys	His	Lys	Asn	Ile	Ile	Asn
		530				535					540				
Leu	Leu	Gly	Ala	Cys	Thr	Gln	Asp	Gly	Pro	Leu	Tyr	Val	Ile	Val	Glu
545					550					555					560
Tyr	Ala	Ser	Lys	Gly	Asn	Leu	Arg	Glu	Tyr	Leu	Gln	Ala	Arg	Arg	Pro
			565						570						575
Pro	Gly	Leu	Glu	Tyr	Cys	Tyr	Asn	Pro	Ser	His	Asn	Pro	Glu	Glu	Gln
			580					585					590		
Leu	Ser	Ser	Lys	Asp	Leu	Val	Ser	Cys	Ala	Tyr	Gln	Val	Ala	Arg	Gly
		595					600					605			
Met	Glu	Tyr	Leu	Ala	Ser	Lys	Lys	Cys	Ile	His	Arg	Asp	Leu	Ala	Ala
		610				615					620				
Arg	Asn	Val	Leu	Val	Thr	Glu	Asp	Asn	Val	Met	Lys	Ile	Ala	Asp	Phe
625					630					635					640
Gly	Leu	Ala	Arg	Asp	Ile	His	His	Ile	Asp	Tyr	Tyr	Lys	Lys	Thr	Thr
			645						650					655	
Asn	Gly	Arg	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro	Glu	Ala	Leu	Phe	Asp
			660					665					670		
Arg	Ile	Tyr	Thr	His	Gln	Ser	Asp	Val	Trp	Ser	Phe	Gly	Val	Leu	Leu
		675					680					685			
Trp	Glu	Ile	Phe	Thr	Leu	Gly	Gly	Ser	Pro	Tyr	Pro	Gly	Val	Pro	Val
	690					695					700				
Glu	Glu	Leu	Phe	Lys	Leu	Leu	Lys	Glu	Gly	His	Arg	Met	Asp	Lys	Pro
705					710					715					720
Ser	Asn	Cys	Thr	Asn	Glu	Leu	Tyr	Met	Met	Met	Arg	Asp	Cys	Trp	His
				725					730					735	
Ala	Val	Pro	Ser	Gln	Arg	Pro	Thr	Phe	Lys	Gln	Leu	Val	Glu	Asp	Leu
			740					745					750		
Asp	Arg	Ile	Val	Ala	Leu	Thr	Ser	Asn	Gln	Glu	Tyr	Leu	Asp	Leu	Ser
		755					760						765		

Met Pro Leu Asp Gln Tyr Ser Pro Ser Phe Pro Asp Thr Arg Ser Ser  
770 775 780

Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro Leu Pro  
785 790 795 800

Glu Glu Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly  
805 810 815

Leu Lys Arg Arg  
820

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 822 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala  
1 5 10 15

Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Ala Gln  
20 25 30

Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly  
35 40 45

Asp Leu Leu Gln Leu Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile  
50 55 60

Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg  
65 70 75 80

Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser  
85 90 95

Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr  
100 105 110

Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp  
115 120 125

Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr  
130 135 140

Lys Pro Asn Arg Met Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys  
145 150 155 160

Met Glu Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe  
165 170 175

Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys  
180 185 190

Asn Gly Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val  
195 200 205











725

730

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 733 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala
 1           5           10           15

Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Asp Ala
 20           25           30

Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Asp Ser Ser Ser Glu
 35           40           45

Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Arg Met Pro Val Ala Pro
 50           55           60

Tyr Trp Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro
 65           70           75           80

Ala Ala Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn
 85           90           95

Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp His
100           105           110

Arg Ile Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile Met
115           120           125

Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val Glu
130           135           140

Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu
145           150           155           160

Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys
165           170           175

Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr Ser
180           185           190

Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val Asn Gly
195           200           205

Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys Thr
210           215           220

Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His Leu Arg
225           230           235           240

Asn Val Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn
245           250           255

Ser Ile Gly Leu Ser His His Ser Ala Trp Leu Thr Val Leu Glu Ala
260           265           270

```



Lys Glu Gly His Arg Met Asp Lys Pro Ser Asn Cys Thr Asn Glu Leu  
 625 630 635 640  
 Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro Ser Gln Arg Pro  
 645 650 655  
 Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile Val Ala Leu Thr  
 660 665 670  
 Ser Asn Gln Glu Tyr Leu Asp Leu Ser Met Pro Leu Asp Gln Tyr Ser  
 675 680 685  
 Pro Ser Phe Pro Asp Thr Arg Ser Ser Thr Cys Ser Ser Gly Glu Asp  
 690 695 700  
 Ser Val Phe Ser His Glu Pro Leu Pro Glu Glu Pro Cys Leu Pro Arg  
 705 710 715 720  
 His Pro Ala Gln Leu Ala Asn Gly Gly Leu Lys Arg Arg  
 725 730

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 300 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala  
 1 5 10 15  
 Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Asp Ala  
 20 25 30  
 Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Ser Ser Ser Glu  
 35 40 45  
 Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Pro Val Ala Pro Tyr Trp  
 50 55 60  
 Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro Ala Ala  
 65 70 75 80  
 Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr  
 85 90 95  
 Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp His Arg Ile  
 100 105 110  
 Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile Met Asp Ser  
 115 120 125  
 Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu  
 130 135 140  
 Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu Arg Ser  
 145 150 155 160  
 Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys Thr Val



Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu  
 145 150 155 160  
 Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys  
 165 170 175  
 Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys Lys Val Tyr Ser  
 180 185 190  
 Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val Asn Gly  
 195 200 205  
 Ser Lys Ile Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys Val  
 210 215 220  
 Ile Met Ala Pro Val Phe Val Gly Gln Ser Thr Gly Lys Glu Thr Thr  
 225 230 235 240  
 Val Ser Gly Ala Gln Val Pro Val Gly Arg Leu Ser Cys Pro Arg Met  
 245 250 255  
 Gly Ser Phe Leu Thr Leu Gln Ala His Thr Leu His Leu Ser Arg Asp  
 260 265 270  
 Leu Ala Thr Ser Pro Arg Thr Ser Asn Arg Gly His Lys Val Glu Val  
 275 280 285  
 Ser Trp Glu Gln Arg Ala Ala Gly Met Gly Gly Ala Gly Leu  
 290 295 300

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATAACGGACC TTGTAGCCTC CAATTCTGTG

30

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCGGCGTTTG AGTCCGCCAT TGGCAAGCTG

30

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 42 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CCAACCTCTA GAGGATCCAC TGGGATGTGG AGCTGGAAGT GC

42

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 42 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTAAGCGGCC GCGGATCCTT ACTACTCCAG GTACAGGGGC GA

42

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCATTTGGAT CCGTCACAGC CAACTCTGC ACCGCT

36

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic"



2

[illegible]